Hepatitis C Pharmacy-based Strategy for Injectors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-05

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is evaluate the acceptability/usage of a newly implemented model of delivery of care, namely a community-pharmacy program, to provide access to medications to treat hepatitis C (HCV), and prevent overdose and HIV, for persons who inject drugs (PWID) with HCV who are in need of treatment. Adults will be enrolled who test positive for HCV at community sites and who agree to linkage to the community-pharmacy program through the use of patient navigators. The primary outcome of the study will be the measure of the number/% of participants who are successfully linked to the community-pharmacy program and assess HCV treatment initiation, completion, and cure. In addition, other outcomes including receipt of other medications (e.g. Naloxone, pre-exposure prophylaxis (PrEP), and medications for opioid use disorders), and self-reported substance use and HIV risk behaviors will also be measured.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users

NCT00194480

Substance-Related Disorders Hepatitis

COMPLETED PHASE4

Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment

NCT01329952

Hepatitis C

UNKNOWN

Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs

NCT02609893

Chronic Hepatitis C

COMPLETED PHASE4

Pharmacist-led Hepatitis C Management

NCT04322981

Hepatitis C Virus Infection

UNKNOWN PHASE4

Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals

NCT02933970

Hepatitis C

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Single-arm, prospective observational study of 40 adult persons who inject drugs (PWID) who screen positive for hepatitis C virus (HCV) with a reactive antibody test at community sites who are offered facilitated linkage to community-pharmacy program through patient navigators. Individuals who are eligible and enroll will complete a baseline survey to assess sociodemographics, substance use, HIV risk behaviors, and awareness of and interest in HCV treatment. After the survey, the participants will be linked to the community-pharmacy program, via the patient navigator, where treatment for HCV and opioid use disorder (OUD), as well as pre-exposure prophylaxis (PrEP), Naloxone and vaccinations, will be offered to participants.

After 6 months, participants will complete a follow-up survey, which will include questions on: whether an evaluation for HCV occurred at the community pharmacy, whether HCV treatment was initiated since baseline visit, substance use, HIV risk behaviors, receipt of medications to treat HCV, opioid use disorder, Naloxone and PrEP receipt, medication adherence, and injecting network.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \>18 years old
2. Reports injecting drugs with 90 days of screening
3. Positive HCV test documented (screening antibody test or viral load test)
4. Not currently taking medications to treat HCV, and never previously treated with direct-acting antivirals (DAAs) for HCV
5. Willing to undergo evaluation for HCV through a community pharmacy program and work with Patient Navigators
6. Provides release of information (ROI) to access community pharmacy program records and/or other HCV treatment providers

Exclusion Criteria

1. People who plan to leave the Seattle area within 6 months
2. Who do not wish to be treated for their HCV infection
3. Who are known to be pregnant
4. Who report impending incarceration that would disrupt clinical care
5. Who are not comfortable reading and speaking English
6. Who report being HIV-positive
7. Who report having end-stage renal disease or require dialysis treatments
8. Who report prior enrolled in (i.e. completed at least the initial intake appointment) the Kelley-Ross pharmacy program for hepatitis C treatment ("One Step Hep C Free")

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No